Case Report

Acquired generalized lipodystrophy type 2-lawrence syndrome: a rare case report

Dhanalakshmi K., Mohinish S.*, Dakshayani B., Mallesh K.

Department of Pediatrics, Bangalore Medical College and Research Institute, Bangalore, Karnataka, India

Received: 25 November 2019
Revised: 24 December 2019
Accepted: 30 December 2019

Correspondence:
Dr. Mohinish S.,
E-mail: monishpaeds@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Lawrence syndrome (Acquired Generalized Lipodystrophy) is a rare disorder, characterized by various dermatological and systemic manifestations such as lipodystrophy, hyperlipidemia, hepatomegaly, acanthosis nigricans and acromegaloid features. Because of its rare occurrence we are reporting a case with similar manifestations in a 10 years old child.

Keywords: Acquired generalized lipodystrophy, Autoimmune hepatitis, Diabetes, Hyperglycemia, Lawrence syndrome, Leptins, Partial dystrophy

INTRODUCTION

Acquired Generalized Lipodystrophy (AGL) is characterized by selective loss of adipose tissue from large regions of the body that develops during childhood and adolescence associated with metabolic disturbances. Ziegler originally described AGL in 1928 in an 11 years old girl. In 1946, Lawrence provided a detailed description and proposed ‘5 major diagnostic criteria’ for the disease.

CASE REPORT

A 10 years old hailing from West Bengal, male child, born out of non-consanguineous marriage, apparently alright till 8 years of age, presented with yellowish discoloration of eyes and skin, associated with abdominal pain for the past 20 days. Complaints of pain noted in the ankle region during walking. Also, complaints of voracious appetite since 1 year and loss of weight noted. There was no weight gain, but weight loss in spite of voracious appetite for the past 1 year. He also gave the history of jaundice 1 year ago, lasted for 20 days. The patient’s vitals at the time of admission were temperature-afebrile, pulse-80/min, blood pressure 96/60 mmHg (100/70 mmHg) anthropometric measurements showed weight-21.5 kg (52.5% of expected), height-131cm (<150 cm) and Body Mass Index 12.54 kg/m² (Figure 1 and 2).

There was generalized loss of subcutaneous fat all over the body with prominent muscles and veins, giving masculine habitus all over the body except abdomen. Eyes, malar bones and ears appeared prominent. Icterus was present in the sclera, mucosa and skin. (Figure 3, 4 and 5) Acanthosis nigricans was observed in the axillae bilaterally. Abdomen was prominent with hepatomegaly of 12 cms, consistency being firm in nature. Laboratory examination revealed complete blood count, urine routine-microscopic examination and renal function test was within normal limit. Erythrocyte Sedimentation Rate-80 mm/1 hour, Fasting Blood Sugar- 101 mg/dl (70-110), Post prandial (2 hour) Blood Sugar- 180 mg/dl (126-140), Serum Fasting Insulin-110.93 mIU/L (2.6-11.1). Liver function test shows Serum total /direct bilirubin = 3.6/1.5 mg/dl Serum Alkaline phosphatase-626 IU/L(80-360), Serum Alanine Transaminase- 820 IU/L (up to55), Serum AST- 753 IU/L,
Serum Albumin-3.4 gm/dl (>3.5 gm/dl), GGT- 205 (12-43), HbA1C- 4.5%.

Lipoprotein- 110 mg/dl (60-150), Serum Very Low-Density Lipoprotein- 95 mg/dl (up to 30). Thyroid function test normal.

Rheumatoid factor, Serum HIV, Serum Hepatitis B Surface Antigen, HCV, HAV, ANA profile were negative. Wilson workup negative. LKM antibodies- 72 (>45) highly positive.

Abdominal ultrasound (Figure 6) showed mild hepatomegaly (16 cm), with diffusely altered echo texture. Chest X-ray revealed no abnormality. Liver biopsy done which confirmed the presence of steatohepatitis with the features of macro vesicular steatosis, and Grade 2 hepatocellular ballooning.
During the hospital stay, the patient developed persistent hyperglycaemia episodes. The patient was started on Atorvastatin (20 mg) and Metformin (500 mg), and paediatric endocrinologist opinion taken. Advised to start steroids Prednisolone (40 mg) for 2 weeks, tapering dose and 5 mg OD to continue, along with Azathioprine 25 mg for 2 weeks followed by 40 mg to continue.

Lawrence-Seip Syndrome is a lipodystrophy disorder in which autoimmune disease, viral/bacterial infections and panniculitis are suspected to be the etiological antecedent suggesting immunologically mediated fat cell lysis leading secondary compensatory metabolic changes via the hypothalamic-pituitary dysfunction.

**Criteria for diagnosing the Lawrence syndrome**

**Essential criteria**

Selective loss fat involving large regions of the body beginning during childhood or adolescence.

**Supportive criteria**

Clinical loss of subcutaneous fat from palms and soles, acanthosis nigricans, hepato-splenomegaly, panniculitis prior to onset associated autoimmune disease.

Laboratory of diabetes Mellitus/Impaired Glucose tolerance, severe hyperinsulinemia (fasting and postprandial), increase serum triglyceride and/or decreased HDL, reduced S. Leptin and/or adiponectin level, anthropometric or MRI evidence of large region of fat loss, MRI evidence of preserved bone marrow fat. The disease usually begins insidiously over months to years in childhood and adolescence, rarely after 30 years of age. Rarely, loss of fat can occur rapidly from one part of the body, followed by quiescent phase for several months or years and reactivate to involve rest of the body. Thus, some patients diagnosed initially as localized or partial lipodystrophy subsequently may develop generalized loss of subcutaneous fat leading to the diagnosis of AGL.

There is lack of Bichat’s fat pad (Empty cheek sign) in the preauricular region, resulting in cadaveric facies, total absence of subcutaneous fat and other metabolically active adipose tissue, preservation of fat deposits in ‘mechanical’ sites-orbit, palms, soles, tongue, breast, vulva, periarticular and epidural region.

Acanthosis nigricans begins in childhood involving the neck, axillae, groin, umbilicus, and nipples. There may be localized or generalized hyperpigmentation, mild hirsutism, and occasional alopecia. Muscular hypertrophy with prominent superficial veins, acromegalic facial and acral features, voracious appetite, increased basal metabolic rate, heat intolerance, osteosclerotic and lytic skeletal changes, masculine features in female.
Metabolic syndrome is less severe than with CGL, in contrast to liver sequelae, which are often lethal.
Insulin resistant Diabetes Mellitus shows severe fasting and postprandial hyperinsulinemia, impaired glucose tolerance, hypertriglyceridemia and sequelae chylomicronemia, pancreatitis, hyperlipidemia, low HDL cholesterol levels, low plasma Leptin levels. True or pseudo clitoromegaly, polycystic ovarian syndrome, menstrual irregularities may be seen. Premature coronary artery or carotid or peripheral vascular disease may be seen.

Renal and CNS abnormalities are usually absent. Hepatomegaly is commonly observed in patients with elevation of serum transaminases due to hepatic steatosis or non-alcoholic steatohepatitis. Some patients may develop cirrhosis with portal hypertension and oesophageal varices, moderate to massive splenomegaly.

Subtypes
Type 1: AGL with panniculitis, Type 2: AGL with Autoimmune Disease Type 3: Idiopathic AGL

In this patient, onset of symptoms was at the age of 8 years and absent family history of similar complaints rules out congenital or familial lipodystrophy. Normal renal function tests rule out Barraquer-Simons syndrome. Bilateral presentation rules out Poland’s syndrome. Absence of muscle wasting, sclerodermatous changes, cataracts and other signs of premature aging rules out Progeria-type syndromes. Cockayne syndrome was ruled out because of absence of growth delay, retinal abnormalities and photosensitivity. Association of DM, hepatitis and AGL can be explained by the autoimmune basis. This case belonged to type 2. This patient presented with generalized loss of subcutaneous fat, acanthosis nigricans, prominent subcutaneous veins, protuberant abdomen and hepatosplenomegaly; hyperglycemia, jaundice; with raised serum transaminases, raised serum fasting insulin, hypertriglyceridemia, hyperlipidemia and low HDL cholesterol levels.

Low fat diet should be recommended. Fibrates are efficacious in lowering serum triglycerides levels, used alone or in combination with low-dose statins. A new option for therapy is Leptin, an adipocyte hormone. Metreleptin (recombinant leptin) treatment of 51 children with lipodystrophies with low leptin levels, a significant improvement was noted in all glycemic control, triglyceride levels, steatohepatitis markers, etc., over 1-year treatment period and effects of treatment continued over 5 years of therapy.

CONCLUSION
This report shows an uncommon case in which AGL is accompanied by autoimmune hepatitis and diabetes mellitus. The insufficient adipose tissue mass leads to excess energy storage in ectopic fat storage organs that finally results in insulin resistance and diabetes.

Coexistence of AGL and diabetes mellitus, although very rare, presents as a totally different disease phenotype. Two conditions in combination can pose significant treatment challenge with regard to both the glycaemic control and the dyslipidaemia. In the absence of metreleptin therapy, a combination of drugs including insulin, metformin, pioglitazone, statins and fibrates could be required at various stages of disease course.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Garg A. Acquired and Inherited Lipodystrophies. N Engl J Med. 2004;350:1220-34.
2. Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Med. 2003 Mar 1;82(2):129-46.
3. Tan SH, Sen P, Tang M. Lipodystrophies. In: Bologna JL, Jorizzo JL, Schaffer JV, eds. Dermatology. 3rd ed. Elsevier; 2012:101(2):1663-1665.
4. Hegele RA, Joy TR, Al-Attar SA, Rutt BK. Lipodystrophies: Windows on adipose biology and metabolism. J Lipid Res. 2007;48:2531-46.
5. Garg A. Lipodystrophy. In: Lowell A, Stiphen I, Barbara A, Paller AS, Wolff K eds. Fitzpatrick’s Dermatology in General medicine. 8th ed. New York: Macgraw Hill; 2013:71(1):755-763.
6. Agarwal AK, Arioglu E, de Almeida S, Akkok N, Taylor SI, Bowcock AM, Barnes R, Garg A. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.Nat Genet 31: 21–3, 2002.
7. Agarwal AK, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab.2002;87:408–11.
8. American Academy of Paediatrics. National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 89: 525–84, 1992.
9. Andreelli F, Hanaire-Broutin H, Laville M, Tauber JP, Riou JP, Thivolet C. Normal reproductive function in leptin-deficient patients with lipoatropic diabetes. J Clin Endocrinol Metab.2000; 85: 715–9.
10. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, Herion D, Kleiner DE, Reynolds J, Premkumar A, Sumner AE, Hoofnagle J, Reitman ML, Taylor SI. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med.2000;133:263–74.
11. Billings JK, Milgraum SS, Gupta AK, Headington JT, Rasmussen JE. Lipoatrophic panniculitis: A possible autoimmune inflammatory disease of fat. Report of three cases. Arch Dermatol 123: 1662–6, 1987.
12. Bjornstad PG, Semb BK, Trygstad O, Seip M. Echocardiographic assessment of cardiac function and morphology in patients with generalised lipodystrophy. Eur J Pediatr. 1985;144:355–9.
13. Bohmer K, Hauner H, Philpen R, Gries FA. Erfolgreiche Insulintherapie bei lipatrophischem Diabetes. Dtsch Med Wochenschr 116: 454–9, 1991.
14. Bolan C, Oral EA, Gorden P, Taylor S, Leitman SF. Intensive, longterm plasma exchange therapy for severe hypertriglyceridemia in acquired generalized lipoatrophy. J Clin Endocrinol Metab 87: 380–4, 2002.
15. Boucher BJ, Cohen RD, Frankel RJ, Mason AS, Broadley G. Partial and total lipoatrophy: Changes in circulating sugar, free fatty acids, insulin and growth hormone following the administration of glucose and of insulin. Clin Endocrinol 2: 111–26, 1973.
16. Bourke B, Powell D. Progression from partial to generalised lipodystrophy—a case report. Ir J Med Sci 161: 458–9, 1992.
17. Brechtel K, Jacob S, Machann J, Hauer B, Nielsen M, Meissner HP, Matthaei S, Haering HU, Claussen CD, and Schick F. Acquired generalized lipoatrophy (AGL): Highly selective MR lipid imaging and localized (1)H-MRS. J Magn Res Imaging 12:306–10, 2000.
18. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96: 519–25, 2001.
19. Catalano PM, Capeless EL, Simmons GM, Robbins DC, Horton ES. Successful pregnancy outcome in association with lipoatrophic diabetes mellitus. Obstet Gynecol 76: 978–9, 1990.
20. Chen D, Misra A, Garg A. Lipodystrophy in HIV-infected patients. J Clin Endocrinol Metab 87: 4845–56, 2002.
21. Coelho PD, Jordao A, Andre O, de Queiroz MV, Eurico-Lisboa P. Rheumatological manifestations of lipoatrophic diabetes. Clin Rheumatol 14: 229–30, 1995.
22. Commens C, O’Neill P, Walker G. Dermatomyositis associated with multifocal lipoatrophy. J Am Acad Dermatol 22: 966–9, 1990.

Cite this article as: Dhanalakshmi K, Mohinish S, Dakshayani B, Mullesh K. Acquired generalized lipodystrophy type 2-lawrence syndrome: a rare case report. Int J Contemp Pediatr 2020;7:437-41.